Literature DB >> 1555493

Models of hepatic drug elimination.

B A Saville1, M R Gray, Y K Tam.   

Abstract

The liver is, by nature, heterogeneous. It contains a complex vascular network for blood flow and a stationary phase consisting of enzymes within parenchymal cells. Several physiological processes, therefore, may combine to give observed ranges in drug elimination. Net changes in concentration are a consequence of a series of steps: uptake of substrate into liver cells, enzymatic reactions within the cells, release of metabolites and unconverted substrate from the cells into the sinusoids, and the net flow of the perfusing medium in the vasculature. In addition, substrate binding to proteins in the blood and in the liver can influence hepatic elimination. An understanding of each of these processes is necessary to fully comprehend the overall process of drug elimination, and these processes must be accounted for, either individually or by grouping and approximation, if a model for drug elimination is to be developed. Existing models of hepatic elimination may be classified according to their treatment of mixing within the vasculature and whether or not the model explicitly accounts for mass transfer between the heterogeneous phases of the liver. Four major classes may be defined: 1. Nonparametric homogeneous models, which assume that either complete mixing or no mixing occurs within the vasculature of the organ. 2. Homogeneous mixing models, which allow for a range of mixing phenomena. 3. Heterogeneous micromixing models, which allow for mass transport between the cells and vasculature and describe mixing within the vasculature on a microscopic level. 4. Heterogeneous compartmental models, which also describe interphase mass transfer but assume complete mixing on a microscopic level, and therefore use a time and spatially averaged approach to model mixing. The utility of these models of hepatic elimination will be critically assessed based upon (1) their ability to account for the influence of the aforementioned physiological processes upon elimination; (2) the data requirements of the model, in addition to its mathematical complexity and ease of use; and (3) the range of compounds and metabolites which may be described using the model.

Mesh:

Year:  1992        PMID: 1555493     DOI: 10.3109/03602539208996290

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  7 in total

1.  Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method.

Authors:  A Hisaka; Y Sugiyama
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

2.  Quantitative evaluation of capacity-limited hepatobiliary transport based on hepatocellular diffusion model by MULTI(FEM).

Authors:  M Higashimori; K Yamaoka; S Fujitani; T Nakagawa
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.

Authors:  V Piotrovskij; A Van Peer
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

4.  Analysis of nonlinear hepatic clearance of a cyclopentapeptide, BQ-123, with the multiple indicator dilution method using the dispersion model.

Authors:  A Hisaka; T Nakamura; Y Sugiyama
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

5.  Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  Reassessing models of hepatic extraction.

Authors:  D Ridgway; J A Tuszynski; Y K Tam
Journal:  J Biol Phys       Date:  2003-03       Impact factor: 1.365

7.  Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations.

Authors:  Lars Ole Schwen; Arne Schenk; Clemens Kreutz; Jens Timmer; María Matilde Bartolomé Rodríguez; Lars Kuepfer; Tobias Preusser
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.